Benzaldehyde thiosemicarbazone derivatives against replicating and nonreplicating Mycobacterium tuberculosis

被引:20
|
作者
Volynets, Galyna P. [1 ]
Tukalo, Michail A. [1 ]
Bdzhola, Volodymyr G. [1 ]
Derkach, Nataliia M. [2 ]
Gumeniuk, Mykola, I [2 ]
Tarnayskiy, Sergiy S. [1 ]
Starosyla, Sergiy A. [1 ]
Yarmoluk, Sergiy M. [1 ]
机构
[1] NAS Ukraine, Inst Mol Biol & Genet, 150 Zabolotnogo St, UA-03143 Kiev, Ukraine
[2] NAMS Ukraine, Natl Inst Phthisiol & Pulmonol, 10 M Amosova St, UA-03038 Kiev, Ukraine
来源
JOURNAL OF ANTIBIOTICS | 2019年 / 72卷 / 04期
关键词
CROSS-RESISTANCE; IN-VITRO; BEDAQUILINE; PERMEABILITY; CLOFAZIMINE; ABSORPTION; ASSAY;
D O I
10.1038/s41429-019-0140-9
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In this article, we report a series of benzaldehyde thiosemicarbazone derivatives possessing high activity toward actively replicating Mycobacterium tuberculosis strain with minimum inhibitory concentration (MIC) values in the range from 0.14 to 2.2 mu M. Among them, two compounds-2-(4-phenethoxybenzylidene)hydrazine-1-carbothioamide (13) and 2-(3-isopropoxybenzylidene)hydrazine-1-carbothioamide (20) also demonstrate submicromolar antimycobacterial activity against M. tuberculosis under hypoxia with MIC values of 0.68 and 0.74 mu M, respectively. The activity of compounds 13 and 20 toward five investigated isoniazid-, rifampicin-, and fluoroquinolone-resistant M. tuberculosis isolates is similar to commercially available antituberculosis drugs. The compounds 13 and 20 possess good ADME properties and have low cytotoxicity toward human liver cells (HepG2). Therefore, 2-(4-phenethoxybenzylidene)hydrazine-1-carbothioamide (13) and 2-(3-isopropoxybenzylidene)hydrazine-1-carbothioamide (20) are valuable candidates for further preclinical studies.
引用
收藏
页码:218 / 224
页数:7
相关论文
共 50 条
  • [1] Benzaldehyde thiosemicarbazone derivatives against replicating and nonreplicating Mycobacterium tuberculosis
    Galyna P. Volynets
    Michail A. Tukalo
    Volodymyr G. Bdzhola
    Nataliia M. Derkach
    Mykola I. Gumeniuk
    Sergiy S. Tarnavskiy
    Sergiy A. Starosyla
    Sergiy M. Yarmoluk
    The Journal of Antibiotics, 2019, 72 : 218 - 224
  • [2] In Vitro and In Vivo Efficacy of β-Lactams against Replicating and Slowly Growing/Nonreplicating Mycobacterium tuberculosis
    Solapure, Suresh
    Dinesh, Neela
    Shandil, Radha
    Ramachandran, Vasanthi
    Sharma, Sreevalli
    Bhattacharjee, Deepa
    Ganguly, Samit
    Reddy, Jitendar
    Ahuja, Vijaykamal
    Panduga, Vijender
    Parab, Manish
    Vishwas, K. G.
    Kumar, Naveen
    Balganesh, Meenakshi
    Balasubramanian, V.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (06) : 2506 - 2510
  • [3] Derivatives of 3-Isoxazolecarboxylic Acid Esters - A Potent and Selective Compound Class against Replicating and Nonreplicating Mycobacterium tuberculosis
    Lilienkampf, Annamaria
    Pieroni, Marco
    Franzblau, Scott G.
    Bishai, William R.
    Kozikowski, Alan P.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2012, 12 (07) : 729 - 734
  • [4] Nitazoxanide Kills Replicating and Nonreplicating Mycobacterium tuberculosis and Evades Resistance
    de Carvalho, Luiz Pedro S.
    Lin, Gang
    Jiang, Xiuju
    Nathan, Carl
    JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (19) : 5789 - 5792
  • [5] Structure-Based Virtual Screening of Benzaldehyde Thiosemicarbazone Derivatives against DNA Gyrase B of Mycobacterium tuberculosis
    Kistan, Andiyappan
    Benedict, Balakrishnan Anna
    Vasanthan, Sundaramoorthy
    PremKumar, Alphonse
    Kullappan, Malathi
    Ambrose, Jenifer Mallavarpu
    Veeraraghavan, Vishnu Priya
    Rengasamy, Gayathri
    Surapaneni, Krishna Mohan
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2021, 2021
  • [6] Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis
    Gold, Ben
    Roberts, Julia
    Ling, Yan
    Quezada, Landys Lopez
    Glasheen, Jou
    Ballinger, Elaine
    Somersan-Karakaya, Selin
    Warrier, Thulasi
    Warren, J. David
    Nathan, Carl
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (10) : 6521 - 6538
  • [7] Aminopyrazinamides: Novel and Specific GyrB Inhibitors that Kill Replicating and Nonreplicating Mycobacterium tuberculosis
    Shirude, Pravin S.
    Madhavapeddi, Prashanti
    Tucker, Julie A.
    Murugan, Kannan
    Patil, Vikas
    Basavarajappa, Halesha
    Raichurkar, Anandkumar V.
    Humnabadkar, Vaishali
    Hussein, Syeed
    Sharma, Sreevalli
    Ramya, V. K.
    Narayan, Chandan B.
    Balganesh, Tanjore S.
    Sambandamurthy, Vasan K.
    ACS CHEMICAL BIOLOGY, 2013, 8 (03) : 519 - 523
  • [8] Structure-Activity Relationships for a Series of Quinoline-Based Compounds Active against Replicating and Nonreplicating Mycobacterium tuberculosis
    Lilienkampf, Annamaria
    Mao, Jialin
    Wan, Baojie
    Wang, Yuehong
    Franzblau, Scott G.
    Kozikowski, Alan P.
    JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (07) : 2109 - 2118
  • [9] Nonreplicating persistence of Mycobacterium tuberculosis
    Wayne, LG
    Sohaskey, CD
    ANNUAL REVIEW OF MICROBIOLOGY, 2001, 55 : 139 - 163
  • [10] Bioluminescence for Assessing Drug Potency against Nonreplicating Mycobacterium tuberculosis
    Vocat, Anthony
    Hartkoorn, Ruben C.
    Lechartier, Benoit
    Zhang, Ming
    Dhar, Neeraj
    Cole, Stewart T.
    Sala, Claudia
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (07) : 4012 - 4019